Currently, the only method of achieving pregnancy in OI subjects is by means of Assisted Reproductive Techniques (ART), such as In Vitro Fertilisation (IVF), which requires ovarian stimulation with high doses of gonadotropins. Various modalities have been tried to improve the outcome in subjects with OI undergoing assisted reproductive technology. These include high-dose FSH treatment, Luteinising Hormone (LH) supplementation, Gonadotropin-Releasing Hormone (GnRH) antagonist cycle, and use of adjuvant treatments such as estradiol priming, growth hormone, L-arginine and Dehydroepiandrosterone (DHEA). These gonadotropin and fertility treatments have negative side effects such as abdominal pain, nausea, vomiting, weight gain, acne, breast pain or tenderness and mood swings, which can lead to discontinued treatment. Further, although gonadotropin treatments are widely used to promote the development of early antral follicles to the pre-ovulatory stage, many OI subjects do not respond to the gonadotropin therapy. Female subjects with OI may have fewer numbers of oocytes during oocyte retrieval; hence, fewer embryos for transfer and fewer chances of conception when compared with a female subject having normal ovarian reserve. These OI subjects may need cancellation of the IVF cycle midway either due to the absence of follicular development, due to lack of oocytes retrieved, lack of successful fertilization or increased pregnancy failure (e.g. high miscarriage rate, which is thought to be due to the initial low oocyte quality found in OI subjects). Generally, IVF is not very helpful for these subjects because as patient age increases, the rate of success decreases dramatically. Although the global success rate of IVF is 25%, which is very low, the success rate in patients between 38-39 years old is 20.8% and for the 40-42, 43-44, 45 and over age ranges it is 13.6%, 5% and 1.9% respectively. This leads many OI subjects to either rely on donor oocyte programs or adoption programs.